Enzyme, Endonuclease, Lysosomal enzyme, Member of the phospholipase D family
01
Overview
Deoxyribonuclease II, lysosomal (DNASE2), is an acid-active lysosomal endonuclease critical for intracellular DNA degradation. It cleaves DNA in the lysosomal compartment under acidic conditions, producing 3'-phosphate termini. DNASE2 operates independently of divalent metal ions and is required for the final degradation of nuclear DNA from apoptotic cells and extruded nuclei during erythropoiesis. This enzyme helps remove DNA waste and prevents immune activation caused by DNA accumulation, playing an essential role in both normal development and immune homeostasis. Deficiencies of DNASE2 result in the failure to properly clear self-DNA, leading to pathologies such as severe neonatal anemia, chronic inflammation, and autoimmunity due to excess interferon production. Molecularly, DNASE2 is synthesized as a precursor that is processed in the lysosome (with forms of ~45 kDa, later processed to 30 and 23 kDa), involving a pseudodimeric structure and PLD-family signature motifs in its active site. No approved drugs currently target DNASE2 directly.
Other names
Deoxyribonuclease-2-alphaDNASE2ADNL2DNase II alphaAcid DNaseDeoxyribonuclease II alphaLysosomal DNase IIR31240_2AIPCSDNLdeoxyribonuclease II, lysosomal
02
Biological functions
DNA degradation/fragmentationClearance of DNA during apoptosisDegradation of DNA from apoptotic cells, cellular debris, and extruded nuclei during red blood cell maturationPrevention of accumulation of immunostimulatory nucleic acids (immune homeostasis)Degradation of mitochondrial DNA to limit inappropriate immune activation
03
Disease associations
Severe neonatal anemia (when DNASE2 is deficient)Chronic inflammation (due to failure to clear DNA)Autoimmunity (due to interferon induction from uncleared “self-DNA”)Other: DNASE2 defects may also relate to developmental disorders but are primarily linked to hematological and immune pathologies
04
Safety considerations
DNASE2 deficiency is linked to severe, sometimes lethal, neonatal anemia due to failure of DNA clearanceDeficiency can provoke inappropriate immune activation and autoimmunity due to uncleared DNA activating inflammatory pathwaysOveractivity is not widely reported as a clinical concern—inhibition would be risky because of risk of inflammation and interferonopathies
05
Interacting drugs
No clinically approved drugs currently target DNASE2 directly. It is not a conventional drug target and no specific inhibitors or activators are clinically used; research and screening efforts for modulators are ongoing but none are standard therapies
06
Biomarkers
DNASE2 gene mutations or activity loss may be used as biomarkers for certain types of anemia and immune dysregulationInterferon levels (type I IFNs) may indirectly reflect defects in DNASE2-mediated clearanceAccumulation of undigested DNA in macrophages or tissues may serve as a pathological biomarker
Beyond the preview
Go deeper on Deoxyribonuclease II, lysosomal (DNASE2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Drug pipeline
Full profile access
Explore the programs pursuing this target and their development progress.
Drug candidates
Developers
Development stage
Clinical trials
Full profile access
Follow the clinical studies evaluating therapies directed at this target.
Trial design
Status
Readouts
Competitive landscape
Full profile access
Compare approaches across drug candidates, modalities, and indications.
Programs
Modalities
Indications
Literature & evidence
Full profile access
Investigate the research and source evidence behind target biology and development.
Publications
Sources
Analysis
Patents
Full profile access
Explore patent activity around therapies and technologies addressing this target.
Patents
Assignees
Technologies
Research & analysis
Full profile access
Connect target biology, drug development, and emerging evidence in your research.
Biology
Development news
Analysis
Bring the full picture into focus.
See how Gosset can support your research on Deoxyribonuclease II, lysosomal (DNASE2).